A Phase 3 interventional study of Udenafil in Dyspnea, Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-06-20.
Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment
Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.
Study design
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 23 is below the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Udenafil 50mg qd po
Drug: Udenafil
Udenafil 50mg qd po
Also known as: Zydena
change of 6-minute walk distance
Time frame: 8 weeks
change of mean pulmonary artery pressure
change of lung function, SGRQ score, Borg index, oxygen saturation, mean pulmonary artery pressure
Time frame: 8 weeks
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital